DA
VYGR icon

Denali Advisors’s Voyager Therapeutics VYGR Stock Holding History

Denali Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,300
Closed -$175K – 545
2023
Q2 		$175K Buy
+15,300
New +$158K 0.06% 228

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Denali Advisors's VYGR Position: Q3 2023 in Review

Denali Advisors sold out of Voyager Therapeutics (VYGR) in Q3 2023, closing a stake of 15,300 shares — an estimated $175K sold.

Denali Advisors first reported a position in VYGR in Q2 2023 and held it in 1 quarter. The position peaked at $175K in Q2 2023. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2023.

  • Denali Advisors reported no remaining Voyager Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Denali Advisors sold 15,300 Voyager Therapeutics shares in Q3 2023, an estimated $175K.
  • Denali Advisors first reported a position in Voyager Therapeutics in Q2 2023 and held it in 1 quarter.
  • Denali Advisors's Voyager Therapeutics position peaked at $175K in Q2 2023.
  • 110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.